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Abstract: Allergic rhinitis is a common inﬂammatory condition
affecting upper airways, nose, and eyes. Allergic rhinitis is a global
health problem and is increasing in prevalence. Allergic rhinitis
patients have often comorbidities asthma being one of the most
common. Up to 40% of patients with allergic rhinitis have asthma
and at least as many as 80% of asthma patients experience symptoms
of allergic rhinitis. Patients with persistent allergic rhinitis should be
evaluated for asthma, and patient with asthma should be properly
evaluated for rhinitis. Allergic rhinitis and its impact on asthma
update is proposing that treatments for one condition, one airway-
one disease, may alleviate the coexisting conditions. Patients need
early recognition, proper diagnosis, effective treatment, and follow-
up. The treatment should be a combined strategy to treat the upper
and lower airways for a good efﬁcacy/safety ratio.
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INTRODUCTION AND BACKGROUND
The burden of allergic rhinitis is evident not only by itsprevalence but also by its impact on individuals and the
society1–3 Allergic rhinitis is a common inﬂammatory condi-
tion affecting upper airways, nose, and eyes. Allergic rhinitis
is a global health problem and is increasing in prevalence.
The prevalence of self-reported allergic rhinitis among ran-
domly identiﬁed people in Europe is 24.5%.4
Allergic rhinitis patients have often comorbidities
asthma being one of the most common. Up to 40% of patients
with allergic rhinitis have asthma and at least as many as 80%
of asthma patients experience symptoms of allergic rhinitis.
Allergic rhinitis is one of the multiple risk factors for the
development of asthma both for adults and children.5,6
Allergic rhinitis increases the risk of asthma hospital-
izations; a retrospective cohort study was conducted to
determine the incremental effect of allergic rhinitis on
healthcare resource use in adults with asthma in UK.7 During
the 12-month follow-up period of 27,303 patients (16 to 55
years of age), patients with documented allergic rhinitis were
signiﬁcantly more likely to be hospitalized for asthma than
were patients with asthma alone (P ¼ 0.0058). The same
study showed also that patients with allergic rhinitis ﬁlled
signiﬁcantly more prescriptions for short-acting beta2-ago-
nists than did patients with asthma alone (P , 0.0001). In
addition, multivariate analysis from the same cohort showed
that a concomitant diagnosis of allergic rhinitis was a signiﬁ-
cant predictor of higher annual costs for asthma medications
(P ¼ 0.0001). The incidence of asthma attacks was signiﬁ-
cantly (P ¼ 0.046) higher among patients with both asthma
and allergic rhinitis than among patients with asthma alone
according a survey including 1490 adults with chronic
asthma.8 This survey also showed that the incidence of emer-
gency room visits was more than twice as high among patients
with both asthma and allergic rhinitis than among patients
with asthma alone.
A survey including children with asthma and comorbid
allergic rhinitis in general practice in UK showed that
presence of concomitant allergic rhinitis with asthma
increases annual number of physician visits (P , 0.0001)
and likelihood of hospitalizations (P ¼ 0.0011).9 This survey
also showed the increased use of short-acting beta2-agonists
(P , 0.0001), increased use of oral corticosteroids (P ,
0.0001) and increased asthma drug costs (P , 0.0001) in
children with allergic rhinitis and asthma.
Patients with persistent allergic rhinitis should be
evaluated for asthma, and patient with asthma should be
properly evaluated for rhinitis. Allergic rhinitis and its impact
on asthma (ARIA) update is proposing that treatments for one
condition, one airway-one disease, may alleviate the coexisting
conditions.1 This is one of the major goals also in the Finnish
Allergy Programme 2008–2018 to decrease the burden of
allergic asthma and rhinitis in the society.10 Patients need early
recognition, proper diagnosis, effective treatment, and follow-
up. The treatment should be a combined strategy to treat the
upper and lower airways for a good efﬁcacy/safety ratio.
DOES TREATMENT OF ALLERGIC RHINITIS
EFFECT ON ASTHMA?
Van Cauwenberge et al reviewed.11 the literature thor-
oughly and came to the conclusion that the treatment of
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allergic rhinitis in asthma patients has been shown to improve
asthma symptoms, pulmonary functions tests, and to reduce
costs. The risk of emergency room treatment or hospitaliza-
tions, exercise-induced asthma, or bronchial hyperresponsive-
ness were also shown to reduce. Furthermore, inadequately
controlled allergic rhinitis in asthmatic patients can contribute
toward increasing asthma exacerbations and poorer symptom
control. These may increase medical resource use. In the
same review van Cauwenberge et al.11 state that leukotriene
modiﬁers are effective in controlling the symptoms of mild to
moderate asthma and the symptoms of rhinitis,12 and the use
of asthma and rhinitis medication is reduced.13 However, a
large number of patients form several studies was needed to
show a 5% difference form placebo.
IS A COMBINATION OF DIFFERENT THERAPIES
MORE EFFECTIVE THAN A SINGLE THERAPY IN
ASTHMA PATIENTS WITH ALLERGIC RHINITIS?
The review by van Cauwenberge targeted also this
question.11 The study by Nathan et al.14 evaluated patient
with persistent asthma treated with the combination of ﬂuti-
casone propionate and salmeterol. Adding montelukast or
ﬂuticasone propionate aqueous nasal spray for the treatment
of seasonal allergic rhinitis resulted in no additional improve-
ments in overall asthma control compared with the combina-
tion therapy with ﬂuticasone and salmeterol alone. The
association of budesonide nasal steroid with a leukotriene
modiﬁer, zaﬁrlukast, was more effective for controlling
nasal symptoms and especially bronchial symptoms than
association of a nasal budesonide with loratadine plus pseu-
doephed-rine.15 Dahl et al have shown that in patients with
pollen-induced allergic rhinitis and asthma the combination of
nasal and inhaled glucocorticosteroids is needed to control the
seasonal increase in nasal and lung symptoms.16
Controlled studies by Walsh17 and by Wilson18 show
that the combination therapy with antihistamines and antileu-
kotrienes is as effective as corticosteroid use in patients with
allergic asthma and seasonal allergic rhinitis. The study by
Roquet et al19 gives evidence in favor of the use of antileu-
kotrienes to treat asthma and rhinitis. However, more data are
needed to understand their full capacity. The combination of
antileukotriene and antihistamine produces an inhibition of
allergen-induced early and late phase airway obstruction in
asthmatics.
Price at al20 showed that in asthmatics with allergic
rhinitis a combination of montelukast and budesonide
resulted signiﬁcantly greater but limited efﬁcacy in reducing
airway obstruction when compared with doubling the dose of
budesonide.
CONCLUSIONS
Allergic rhinitis and asthma often coexist, suggesting the
concept of “one airway, one disease.” This is because allergy
is a systemic disease, which causes symptoms in different
target organs. The most important factor in understanding
the nature of asthma and allergy is to understand the
inﬂammatory reaction involved in these diseases. Allergic in-
ﬂammation causes symptoms and has to be controlled as well
as possible with treatment. Whether or not treating allergic
rhinitis improves asthma per se, it is important to recognize
and treat allergic rhinitis in patients with asthma to improve
there symptoms and quality of life.
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